U.S. markets closed
  • S&P Futures

    4,571.00
    +13.00 (+0.29%)
     
  • Dow Futures

    35,679.00
    +59.00 (+0.17%)
     
  • Nasdaq Futures

    15,570.50
    +74.75 (+0.48%)
     
  • Russell 2000 Futures

    2,317.50
    +7.20 (+0.31%)
     
  • Crude Oil

    83.65
    -0.11 (-0.13%)
     
  • Gold

    1,806.90
    +0.10 (+0.01%)
     
  • Silver

    24.53
    -0.06 (-0.23%)
     
  • EUR/USD

    1.1608
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.6350
    -0.0200 (-1.21%)
     
  • Vix

    15.24
    -0.19 (-1.23%)
     
  • GBP/USD

    1.3766
    -0.0002 (-0.02%)
     
  • USD/JPY

    113.8300
    +0.1310 (+0.12%)
     
  • BTC-USD

    62,785.56
    +1,100.64 (+1.78%)
     
  • CMC Crypto 200

    1,508.11
    +1,265.43 (+521.44%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Nikkei 225

    29,109.36
    +508.95 (+1.78%)
     

ChromaDex launches Tru Niagen® in Walmart Stores; Shares Pop 7%

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ChromaDex Corporation (CDXC), a nutraceutical company, launched its flagship healthy aging nutrient Tru Niagen® in 3,800 Walmart stores across the United States. Shares were trading around 7% higher in early trade on Tuesday at the time of writing.

Walmart Inc. (WMT) is the first major retailer to offer Tru Niagen® in its stores. The nutrient will be offered in two serving sizes, 100mg, and 300mg, and will also be available online with same-day delivery and pick-up options at select locations.

Tru Niagen® is a distinctive form of vitamin B3 that is clinically proven to enhance NAD+, a vital coenzyme, naturally produced in the body and said to reduce to up to 50% in the 40-60 years age group. A 300gm daily serving of the nutrient is said to increase NAD+ levels by 40 – 50%, thereby reducing the impact of aging and daily wear and tear on the body, and helping consumers Age Better®.

Before the launch, Niagen had acquired all of the necessary regulatory approvals. (See ChromaDex stock analysis on TipRanks)

Following the launch, H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on the stock with a price target of $11, which implies 11.8% upside potential to current levels.

Selvaraju said, “ChromaDex expects continued, steady revenue growth driven by its global e-commerce business, as well as existing and new strategic partners. We continue to expect positive impact on top-line growth driven by ChromaDex’s relationships with Watsons, Walmart and Nestlé Health Sciences.”

Consensus among analysts is a Strong Buy based on 4 unanimous Buys. The CDXC average analyst price target stands at $14.50 and implies upside potential of 47.3% to current levels. Shares have gained around 93% year-to-date.

Related News:
Vulcan Inks $1.294B Cash Deal to Buy U.S. Concrete
Biogen’s ADUHELM Receives Accelerated Approval from FDA; Shares Soar 38%
UiPath Earnings Preview: Here’s What to Watch For

More recent articles from Smarter Analyst: